Trial Outcomes & Findings for A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Psoriasis (NCT NCT00307437)

Last Updated: 2013-01-24

Results Overview

Number of participants achieving greater than or equal to 75 percent improvement in PASI at Week 12. PASI is a widely used tool for the measurement of severity of psoriasis. This is a test of how bad a person's psoriasis is. The scale combines redness, scaling, and thickness, as well as overall body involvement to determine the PASI score. The scale ranges from 0 (best) to 72 (worst).

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

1230 participants

Primary outcome timeframe

Week 0 to Week 12

Results posted on

2013-01-24

Participant Flow

In this trial, 1230 participants were randomized to either placebo or ustekinumab (CNTO 1275). There were 70 sites in North America and Europe.

2 participants from placebo group (in controlled period \[CP\]) after completing the CP did not crossover to the Placebo -\> Ustekinumab 90 mg (after CP) treatment group and they are not included in this group (after CP). Thus, 1199 participants completed the 1st period (CP); however, only 1197 participants started the 2nd period (after CP).

Participant milestones

Participant milestones
Measure	Placebo (CP) Controlled period (Week 0-12) - Placebo group	Ustekinumab 45 mg (CP) Controlled period (Week 0-12) - Ustekinumab 45 mg group	Ustekinumab 90 mg (CP) Controlled period (Week 0-12) - Ustekinumab 90 mg group	Placebo -> Ustekinumab 45 mg (After CP) After Controlled period (Week 12-264) - patients receiving Placebo at Weeks 0 and 4 -\> receiving ustekinumab 45 mg q12wk or q8wk from Week 12 to Week 244. Some patients in this group dose escalated from ustekinumab 45 mg to 90 mg after Week 52.	Placebo -> Ustekinumab 90 mg (After CP) After Controlled period (Week 12-264) - patients receiving Placebo at Weeks 0 and 4 -\> receiving ustekinumab 90 mg q12wk or q8wk from Week 12 to Week 244.	Ustekinumab 45 mg (After CP) After Controlled period (Week 12-264) - patients receiving ustekinumab 45 mg at Weeks 0 and 4 -\> receiving ustekinumab 45 mg q12wk or q8wk from Week 16 to Week 244. Some patients in this group dose escalated from ustekinumab 45 mg to 90 mg after Week 52.	Ustekinumab 90 mg (After CP) After Controlled period (Week 12-264) - patients receiving ustekinumab 90 mg at Weeks 0 and 4 -\> receiving ustekinumab 90 mg q12wk or q8wk from Week 16 to Week 244.
Controlled Period STARTED	410	409	411	0	0	0	0
Controlled Period COMPLETED	394	403	402	0	0	0	0
Controlled Period NOT COMPLETED	16	6	9	0	0	0	0
After Controlled Period STARTED	0	0	0	197	195	403	402
After Controlled Period COMPLETED	0	0	0	139	140	281	289
After Controlled Period NOT COMPLETED	0	0	0	58	55	122	113

Reasons for withdrawal

Reasons for withdrawal
Measure	Placebo (CP) Controlled period (Week 0-12) - Placebo group	Ustekinumab 45 mg (CP) Controlled period (Week 0-12) - Ustekinumab 45 mg group	Ustekinumab 90 mg (CP) Controlled period (Week 0-12) - Ustekinumab 90 mg group	Placebo -> Ustekinumab 45 mg (After CP) After Controlled period (Week 12-264) - patients receiving Placebo at Weeks 0 and 4 -\> receiving ustekinumab 45 mg q12wk or q8wk from Week 12 to Week 244. Some patients in this group dose escalated from ustekinumab 45 mg to 90 mg after Week 52.	Placebo -> Ustekinumab 90 mg (After CP) After Controlled period (Week 12-264) - patients receiving Placebo at Weeks 0 and 4 -\> receiving ustekinumab 90 mg q12wk or q8wk from Week 12 to Week 244.	Ustekinumab 45 mg (After CP) After Controlled period (Week 12-264) - patients receiving ustekinumab 45 mg at Weeks 0 and 4 -\> receiving ustekinumab 45 mg q12wk or q8wk from Week 16 to Week 244. Some patients in this group dose escalated from ustekinumab 45 mg to 90 mg after Week 52.	Ustekinumab 90 mg (After CP) After Controlled period (Week 12-264) - patients receiving ustekinumab 90 mg at Weeks 0 and 4 -\> receiving ustekinumab 90 mg q12wk or q8wk from Week 16 to Week 244.
Controlled Period Adverse Event	7	2	5	0	0	0	0
Controlled Period Death	0	0	1	0	0	0	0
Controlled Period Lack of Efficacy	2	0	0	0	0	0	0
Controlled Period Lost to Follow-up	2	3	0	0	0	0	0
Controlled Period Other	5	1	3	0	0	0	0
After Controlled Period Adverse Event	0	0	0	18	16	31	40
After Controlled Period Death	0	0	0	3	1	1	3
After Controlled Period Lack of Efficacy	0	0	0	15	17	37	24
After Controlled Period Lost to Follow-up	0	0	0	7	12	13	18
After Controlled Period Other	0	0	0	15	9	40	28

Baseline Characteristics

A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Psoriasis

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Group I: Placebo n=410 Participants Placebo participants received placebo at Weeks 0 and 4. At Weeks 12 and 16, placebo crossed over to receive ustekinumab 45 mg or 90 mg. Treatments after Week 16 were dependent on clinical response.	Group II: Ustekinumab 45 mg n=409 Participants Participants received ustekinumab 45 mg at Weeks 0, 4 and 16. Treatments after Week 16 were dependent on clinical response. At Week 28, participants who achieved a greater than and equal to 50 percentage but less than 75 percentage improvement in PASI were re-randomized to continue 45 mg every 12 week or dose adjust to 45 mg every 8 week dosing.	Group III: Ustekinumab 90 mg n=411 Participants Participants received ustekinumab 90 mg at Weeks 0, 4 and 16. Treatments after Week 16 were dependent on clinical response. At Week 28, participants who achieved a greater than and equal 50 percentage but less than 75 percentage improvement in PASI were re-randomized to continue 90 mg every 12 week or dose adjust to 90 mg every 8 week dosing.	Total n=1230 Participants Total of all reporting groups
Age Continuous	47.0 years STANDARD_DEVIATION 12.47 • n=5 Participants	45.1 years STANDARD_DEVIATION 12.06 • n=7 Participants	46.6 years STANDARD_DEVIATION 12.14 • n=5 Participants	46.2 years STANDARD_DEVIATION 12.24 • n=4 Participants
Sex: Female, Male Female	127 Participants n=5 Participants	126 Participants n=7 Participants	137 Participants n=5 Participants	390 Participants n=4 Participants
Sex: Female, Male Male	283 Participants n=5 Participants	283 Participants n=7 Participants	274 Participants n=5 Participants	840 Participants n=4 Participants

PRIMARY outcome

Timeframe: Week 0 to Week 12

Population: Intent to treat. All participants randomized were included in the analysis according to the assigned treatment groups. Participant is considered a non- responder if the participant has used any pre-specified prohibited medications or discontinued due to lack of efficacy or had missing data at Week 12.

Outcome measures

Outcome measures
Measure	Group I: Placebo n=410 Participants Placebo participants received placebo at Weeks 0 and 4. At Weeks 12 and 16, placebo crossed over to receive ustekinumab 45 mg or 90 mg. Treatments after Week 16 were dependent on clinical response.	Group II: Ustekinumab 45 mg n=409 Participants Partcipants received ustekinumab 45 mg at Weeks 0, 4 and 16. Treatments after Week 16 were dependent on clinical response. At Week 28, partcipants who achieved a greater than and equal 50 percentage but less than 75 percentage improvement in PASI were re-randomized to continue 45 mg every 12 week or dose adjust to 45 mg every 8 week dosing.	Group III: Ustekinumab 90 mg n=411 Participants Partcipants received ustekinumab 90 mg at Weeks 0, 4 and 16. Treatments after Week 16 were dependent on clinical response. At Week 28, partcipants who achieved a greater than and equal 50 percentage but less than 75 percentage improvement in PASI were re-randomized to continue 90 mg every 12 week or dose adjust to 90 mg every 8 week dosing.	Group 4: Ustekinumab 90 mg Every 12 Weeks Participants received ustekinumab 90 mg at Weeks 0, 4, 16, 28 and 40.	Group 5: Combined (8 Week Dosing) Combined Groups 1 and 3 (dosing every 8 weeks)	Group 6: Combined (12 Week Dosing) Combined Groups 2 and 4 (dosing every 12 weeks)
Number of Participants With Psoriasis Area and Severity Index (PASI) Score of 75 Percent or Above at Week 12	15 Participants	273 Participants	311 Participants	—	—	—

SECONDARY outcome

Timeframe: Week 12

Population: Intent to treat. All participants were included in the analysis according to the assigned treatment groups. Participant is considered a non- responder if the participant has used any pre-specified prohibited medications or discontinued due to lack of efficacy or had missing data at Week 12.

Number of participants achieving a physician global assessment (PGA) (0 \[none\] to 5 \[severe\]) of cleared or minimal at Week 12. The PGA is 7-point scale used in clinical trials of various diseases. In this the physician checks the state of the disease and gives them score from 0 (clear) to 5 (severe).

Outcome measures

Outcome measures
Measure	Group I: Placebo n=410 Participants Placebo participants received placebo at Weeks 0 and 4. At Weeks 12 and 16, placebo crossed over to receive ustekinumab 45 mg or 90 mg. Treatments after Week 16 were dependent on clinical response.	Group II: Ustekinumab 45 mg n=409 Participants Partcipants received ustekinumab 45 mg at Weeks 0, 4 and 16. Treatments after Week 16 were dependent on clinical response. At Week 28, partcipants who achieved a greater than and equal 50 percentage but less than 75 percentage improvement in PASI were re-randomized to continue 45 mg every 12 week or dose adjust to 45 mg every 8 week dosing.	Group III: Ustekinumab 90 mg n=411 Participants Partcipants received ustekinumab 90 mg at Weeks 0, 4 and 16. Treatments after Week 16 were dependent on clinical response. At Week 28, partcipants who achieved a greater than and equal 50 percentage but less than 75 percentage improvement in PASI were re-randomized to continue 90 mg every 12 week or dose adjust to 90 mg every 8 week dosing.	Group 4: Ustekinumab 90 mg Every 12 Weeks Participants received ustekinumab 90 mg at Weeks 0, 4, 16, 28 and 40.	Group 5: Combined (8 Week Dosing) Combined Groups 1 and 3 (dosing every 8 weeks)	Group 6: Combined (12 Week Dosing) Combined Groups 2 and 4 (dosing every 12 weeks)
Number of Participants With Physician Global Assessment (PGA) of Cleared or Minimal at Week 12	18 Participants	277 Participants	300 Participants	—	—	—

SECONDARY outcome

Timeframe: Baseline to Week 12

Population: Participants were included in the analysis according to the assigned treatment groups. Zero change is imputed if the partcipant has used any pre-specified prohibited medications or discontinued due to lack of efficacy. Other missing data were not imputed.

Change in Dermatology Life Quality Index (DLQI) from baseline at Week 12. The DLQI is a 10-item questionnaire, that in addition to evaluating overall quality of life, can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. Scores range from 0 (no impairment in quality of life) to 30 (most impairment in quality of life).

Outcome measures

Outcome measures
Measure	Group I: Placebo n=400 Participants Placebo participants received placebo at Weeks 0 and 4. At Weeks 12 and 16, placebo crossed over to receive ustekinumab 45 mg or 90 mg. Treatments after Week 16 were dependent on clinical response.	Group II: Ustekinumab 45 mg n=401 Participants Partcipants received ustekinumab 45 mg at Weeks 0, 4 and 16. Treatments after Week 16 were dependent on clinical response. At Week 28, partcipants who achieved a greater than and equal 50 percentage but less than 75 percentage improvement in PASI were re-randomized to continue 45 mg every 12 week or dose adjust to 45 mg every 8 week dosing.	Group III: Ustekinumab 90 mg n=402 Participants Partcipants received ustekinumab 90 mg at Weeks 0, 4 and 16. Treatments after Week 16 were dependent on clinical response. At Week 28, partcipants who achieved a greater than and equal 50 percentage but less than 75 percentage improvement in PASI were re-randomized to continue 90 mg every 12 week or dose adjust to 90 mg every 8 week dosing.	Group 4: Ustekinumab 90 mg Every 12 Weeks Participants received ustekinumab 90 mg at Weeks 0, 4, 16, 28 and 40.	Group 5: Combined (8 Week Dosing) Combined Groups 1 and 3 (dosing every 8 weeks)	Group 6: Combined (12 Week Dosing) Combined Groups 2 and 4 (dosing every 12 weeks)
Change in Dermatology Life Quality Index (DLQI) at Week 12	-0.5 Units on a scale Interval -4.0 to 3.0	-8.0 Units on a scale Interval -14.0 to -4.0	-9.0 Units on a scale Interval -14.0 to -5.0	—	—	—

SECONDARY outcome

Timeframe: Week 40 to Week 52

Population: All participants randomized at Week 28 were included in the analysis according to the assigned treatment groups. Participant is considered a non- responder if the participant has used any pre-specified prohibited medications or discontinued due to lack of efficacy.

Number of visits at which participants randomized at Week 28 achieved at least 75 percent improvement from baseline in PASI from Week 40 through Week 52 in participants randomized at Week 28. PASI is a widely used tool for the measurement of severity of psoriasis. This is a test of how bad a person's psoriasis is. The scale combines redness, scaling, and thickness, as well as overall body involvement to determine the PASI score. The scale ranges from 0 (best) to 72 (worst).

Outcome measures

Outcome measures
Measure	Group I: Placebo n=45 Participants Placebo participants received placebo at Weeks 0 and 4. At Weeks 12 and 16, placebo crossed over to receive ustekinumab 45 mg or 90 mg. Treatments after Week 16 were dependent on clinical response.	Group II: Ustekinumab 45 mg n=48 Participants Partcipants received ustekinumab 45 mg at Weeks 0, 4 and 16. Treatments after Week 16 were dependent on clinical response. At Week 28, partcipants who achieved a greater than and equal 50 percentage but less than 75 percentage improvement in PASI were re-randomized to continue 45 mg every 12 week or dose adjust to 45 mg every 8 week dosing.	Group III: Ustekinumab 90 mg n=32 Participants Partcipants received ustekinumab 90 mg at Weeks 0, 4 and 16. Treatments after Week 16 were dependent on clinical response. At Week 28, partcipants who achieved a greater than and equal 50 percentage but less than 75 percentage improvement in PASI were re-randomized to continue 90 mg every 12 week or dose adjust to 90 mg every 8 week dosing.	Group 4: Ustekinumab 90 mg Every 12 Weeks n=33 Participants Participants received ustekinumab 90 mg at Weeks 0, 4, 16, 28 and 40.	Group 5: Combined (8 Week Dosing) n=77 Participants Combined Groups 1 and 3 (dosing every 8 weeks)	Group 6: Combined (12 Week Dosing) n=81 Participants Combined Groups 2 and 4 (dosing every 12 weeks)
Number of Participants Visits With Psoriasis Area and Severity Index (PASI) 75 From Week 40 Through Week 52	0 Participants Interval 0.0 to 2.0	1 Participants Interval 0.0 to 3.0	3 Participants Interval 1.5 to 4.0	1 Participants Interval 0.0 to 4.0	2 Participants Interval 0.0 to 4.0	1 Participants Interval 0.0 to 3.0

Adverse Events

Placebo (CP)

Serious events: 8 serious events

Other events: 116 other events

Deaths: 0 deaths

Ustekinumab 45 mg (CP)

Serious events: 8 serious events

Other events: 119 other events

Deaths: 0 deaths

Ustekinumab 90 mg (CP)

Serious events: 5 serious events

Other events: 114 other events

Deaths: 0 deaths

Placebo -> Ustekinumab 45 mg (After CP)

Serious events: 40 serious events

Other events: 168 other events

Deaths: 0 deaths

Placebo -> Ustekinumab 90 mg (After CP)

Serious events: 41 serious events

Other events: 159 other events

Deaths: 0 deaths

Ustekinumab 45 mg (After CP)

Serious events: 81 serious events

Other events: 342 other events

Deaths: 0 deaths

Ustekinumab 90 mg (After CP)

Serious events: 73 serious events

Other events: 343 other events

Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure	Placebo (CP) n=410 participants at risk Controlled period (Week 0-12) - Placebo group	Ustekinumab 45 mg (CP) n=409 participants at risk Controlled period (Week 0-12) - Ustekinumab 45 mg group	Ustekinumab 90 mg (CP) n=411 participants at risk Controlled period (Week 0-12) - Ustekinumab 90 mg group	Placebo -> Ustekinumab 45 mg (After CP) n=197 participants at risk After Controlled period (Week 12-264) - patients receiving Placebo at Weeks 0 and 4 -\> receiving ustekinumab 45 mg q12wk or q8wk from Week 12 to Week 244. Some patients in this group dose escalated from ustekinumab 45 mg to 90 mg after Week 52.	Placebo -> Ustekinumab 90 mg (After CP) n=195 participants at risk After Controlled period (Week 12-264) - patients receiving Placebo at Weeks 0 and 4 -\> receiving ustekinumab 90 mg q12wk or q8wk from Week 12 to Week 244.	Ustekinumab 45 mg (After CP) n=407 participants at risk After Controlled period (Week 12-264) - patients receiving ustekinumab 45 mg at Weeks 0 and 4 -\> receiving ustekinumab 45 mg q12wk or q8wk from Week 16 to Week 244. Some patients in this group dose escalated from ustekinumab 45 mg to 90 mg after Week 52.	Ustekinumab 90 mg (After CP) n=409 participants at risk After Controlled period (Week 12-264) - patients receiving ustekinumab 90 mg at Weeks 0 and 4 -\> receiving ustekinumab 90 mg q12wk or q8wk from Week 16 to Week 244.
Gastrointestinal disorders Upper gastrointestinal haemorrhage	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Gastrointestinal disorders Salivary gland calculus	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Gastrointestinal disorders Pancreatitis acute	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Gastrointestinal disorders Peptic ulcer	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Gastrointestinal disorders Peritonitis	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Blood and lymphatic system disorders Lymphoid tissue hyperplasia	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Cardiac disorders Acute coronary syndrome	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Cardiac disorders Acute myocardial infarction	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Cardiac disorders Angina pectoris	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Cardiac disorders Angina unstable	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	1.0% 2/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.49% 2/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Cardiac disorders Atrial fibrillation	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.74% 3/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.49% 2/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Cardiac disorders Atrioventricular block second degree	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Cardiac disorders Bradycardia	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Cardiac disorders Cardiac arrest	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Cardiac disorders Cardiac failure congestive	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.49% 2/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Cardiac disorders Cardiovascular disorder	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Cardiac disorders Congestive cardiomyopathy	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Cardiac disorders Coronary artery disease	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	1.0% 2/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	1.0% 2/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	1.5% 6/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Cardiac disorders Coronary artery stenosis	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Cardiac disorders Myocardial infarction	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	1.5% 3/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	1.2% 5/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.73% 3/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Cardiac disorders Myocardial ischaemia	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Cardiac disorders Myocarditis	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Cardiac disorders Palpitations	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Cardiac disorders Supraventricular tachycardia	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Cardiac disorders Tachycardia	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Cardiac disorders Ventricular extrasystoles	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Cardiac disorders Ventricular fibrillation	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Ear and labyrinth disorders Sudden hearing loss	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Ear and labyrinth disorders Vertigo	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Endocrine disorders Goitre	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.49% 2/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Eye disorders Vitreous haemorrhage	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Gastrointestinal disorders Abdominal hernia obstructive	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Gastrointestinal disorders Abdominal pain	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Gastrointestinal disorders Abdominal pain upper	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Gastrointestinal disorders Ascites	0.24% 1/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Gastrointestinal disorders Colitis	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Gastrointestinal disorders Constipation	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Gastrointestinal disorders Diverticular perforation	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	1.0% 2/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Gastrointestinal disorders Diverticulum	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Gastrointestinal disorders Dysphagia	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Gastrointestinal disorders Faecaloma	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Gastrointestinal disorders Gastric ulcer	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Gastrointestinal disorders Gastritis	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Gastrointestinal disorders Gastrointestinal haemorrhage	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Gastrointestinal disorders Gastrooesophageal reflux disease	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Gastrointestinal disorders Inguinal hernia	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.49% 2/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Gastrointestinal disorders Intestinal perforation	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Gastrointestinal disorders Oesophageal varices haemorrhage	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Gastrointestinal disorders Pancreatitis	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.49% 2/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
General disorders Chest pain	0.24% 1/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	1.0% 2/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.49% 2/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	1.7% 7/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
General disorders Cyst	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
General disorders Device breakage	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
General disorders Hernia	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
General disorders Multi-organ failure	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
General disorders Non-cardiac chest pain	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Hepatobiliary disorders Biliary colic	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Hepatobiliary disorders Cholecystitis	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.98% 4/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Hepatobiliary disorders Cholecystitis acute	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Hepatobiliary disorders Cholelithiasis	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	1.0% 2/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Hepatobiliary disorders Cholestasis	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Hepatobiliary disorders Cryptogenic cirrhosis	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Hepatobiliary disorders Hepatosplenomegaly	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Immune system disorders Anaphylactoid reaction	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Immune system disorders Drug hypersensitivity	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Infections and infestations Abdominal abscess	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Infections and infestations Anal abscess	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Infections and infestations Appendicitis	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Infections and infestations Arthritis bacterial	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Infections and infestations Bacteraemia	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Infections and infestations Bronchitis	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Infections and infestations Cellulitis	0.49% 2/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.49% 2/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Infections and infestations Diverticulitis	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	1.5% 3/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.49% 2/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Infections and infestations Erysipelas	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Infections and infestations Gastroenteritis	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Infections and infestations Genitourinary tract infection	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Infections and infestations H1N1 influenza	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Infections and infestations Herpes zoster	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Infections and infestations Influenza	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Infections and infestations Lobar pneumonia	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Infections and infestations Meningitis	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Infections and infestations Osteomyelitis	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Infections and infestations Pneumonia	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Infections and infestations Pneumonia streptococcal	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Infections and infestations Postoperative wound infection	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Infections and infestations Sepsis	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Infections and infestations Septic shock	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Infections and infestations Staphylococcal abscess	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Infections and infestations Streptococcal infection	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Infections and infestations Streptococcal sepsis	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Infections and infestations Tooth abscess	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Infections and infestations Urinary tract infection	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Infections and infestations Wound infection staphylococcal	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Injury, poisoning and procedural complications Anastomotic ulcer	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Injury, poisoning and procedural complications Animal bite	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Injury, poisoning and procedural complications Ankle fracture	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.49% 2/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Injury, poisoning and procedural complications Carbon monoxide poisoning	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Injury, poisoning and procedural complications Cartilage injury	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Injury, poisoning and procedural complications Cervical vertebral fracture	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Injury, poisoning and procedural complications Clavicle fracture	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Injury, poisoning and procedural complications Concussion	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Injury, poisoning and procedural complications Facial bones fracture	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Injury, poisoning and procedural complications Gastrointestinal anastomotic leak	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Injury, poisoning and procedural complications Head injury	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Injury, poisoning and procedural complications In-stent arterial restenosis	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Injury, poisoning and procedural complications Laceration	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Injury, poisoning and procedural complications Limb traumatic amputation	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Injury, poisoning and procedural complications Meniscus lesion	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.49% 2/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Injury, poisoning and procedural complications Multiple injuries	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Injury, poisoning and procedural complications Muscle strain	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Injury, poisoning and procedural complications Open fracture	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Injury, poisoning and procedural complications Post procedural complication	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Injury, poisoning and procedural complications Post procedural haemorrhage	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.49% 2/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Injury, poisoning and procedural complications Postoperative ileus	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Injury, poisoning and procedural complications Radius fracture	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Injury, poisoning and procedural complications Rib fracture	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Injury, poisoning and procedural complications Seroma	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Injury, poisoning and procedural complications Tendon rupture	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Injury, poisoning and procedural complications Traumatic liver injury	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Injury, poisoning and procedural complications Wrist fracture	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Investigations Liver function test abnormal	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Metabolism and nutrition disorders Diabetic ketoacidosis	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Metabolism and nutrition disorders Gout	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Metabolism and nutrition disorders Hyperglycaemic hyperosmolar nonketotic syndrome	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Metabolism and nutrition disorders Hypokalaemia	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Metabolism and nutrition disorders Hyponatraemia	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Metabolism and nutrition disorders Obesity	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Musculoskeletal and connective tissue disorders Back pain	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Musculoskeletal and connective tissue disorders Bursitis	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Musculoskeletal and connective tissue disorders Dactylitis	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Musculoskeletal and connective tissue disorders Flank pain	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Musculoskeletal and connective tissue disorders Intervertebral disc degeneration	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Musculoskeletal and connective tissue disorders Intervertebral disc protrusion	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.49% 2/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	1.0% 2/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.49% 2/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Musculoskeletal and connective tissue disorders Osteoarthritis	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.49% 2/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Musculoskeletal and connective tissue disorders Pain in extremity	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Musculoskeletal and connective tissue disorders Psoriatic arthropathy	0.24% 1/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.49% 2/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Musculoskeletal and connective tissue disorders Rotator cuff syndrome	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Musculoskeletal and connective tissue disorders Spinal disorder	0.24% 1/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Adenocarcinoma	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Adenocarcinoma pancreas	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Benign neoplasm of thyroid gland	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Bladder cancer	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Bladder transitional cell carcinoma	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Breast cancer	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Chronic lymphocytic leukaemia	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Colon cancer	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.49% 2/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Endometrial cancer	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Glomus tumour	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Hepatic neoplasm malignant	0.24% 1/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Malignant melanoma in situ	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Meningioma benign	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Multiple myeloma	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Oesophageal carcinoma	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Ovarian cancer metastatic	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Prostate cancer	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.49% 2/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.73% 3/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Rectal adenoma	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Renal cancer metastatic	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Renal cell carcinoma	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Small cell lung cancer stage unspecified	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Squamous cell carcinoma	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Testis cancer	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Tongue neoplasm malignant stage unspecified	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Nervous system disorders Benign intracranial hypertension	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Nervous system disorders Cervicobrachial syndrome	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Nervous system disorders Complicated migraine	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Nervous system disorders Convulsion	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Nervous system disorders Dementia Alzheimer's type	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Nervous system disorders Dizziness	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Nervous system disorders Facial paresis	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Nervous system disorders Headache	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Nervous system disorders Hydrocephalus	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Nervous system disorders Loss of consciousness	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Nervous system disorders Migraine	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Nervous system disorders Myelopathy	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Nervous system disorders Nerve compression	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Nervous system disorders Neuralgia	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Nervous system disorders Posterior reversible encephalopathy syndrome	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Nervous system disorders Sciatica	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Nervous system disorders Syncope	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.49% 2/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Nervous system disorders Transient ischaemic attack	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Nervous system disorders VIIth nerve paralysis	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Pregnancy, puerperium and perinatal conditions Abortion spontaneous	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Psychiatric disorders Alcohol withdrawal syndrome	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Psychiatric disorders Confusional state	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Psychiatric disorders Depression	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Psychiatric disorders Drug abuse	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Psychiatric disorders Panic attack	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Psychiatric disorders Post-traumatic stress disorder	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Psychiatric disorders Schizophrenia	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Psychiatric disorders Substance abuse	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Psychiatric disorders Suicide attempt	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Renal and urinary disorders Calculus ureteric	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Renal and urinary disorders Haematuria	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Renal and urinary disorders Nephrolithiasis	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	1.5% 3/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.98% 4/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Renal and urinary disorders Renal colic	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.49% 2/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.49% 2/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Renal and urinary disorders Renal failure acute	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Reproductive system and breast disorders Cervical dysplasia	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Reproductive system and breast disorders Endometrial hypertrophy	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Reproductive system and breast disorders Menometrorrhagia	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Reproductive system and breast disorders Ovarian torsion	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Reproductive system and breast disorders Uterine haemorrhage	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Reproductive system and breast disorders Uterine polyp	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Respiratory, thoracic and mediastinal disorders Acute respiratory distress syndrome	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Respiratory, thoracic and mediastinal disorders Aspiration	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Respiratory, thoracic and mediastinal disorders Asthma	0.24% 1/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Respiratory, thoracic and mediastinal disorders Bronchitis chronic	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Respiratory, thoracic and mediastinal disorders Chronic obstructive pulmonary disease	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Respiratory, thoracic and mediastinal disorders Diaphragmatic hernia	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Respiratory, thoracic and mediastinal disorders Epistaxis	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Respiratory, thoracic and mediastinal disorders Nasal septum deviation	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Respiratory, thoracic and mediastinal disorders Pneumothorax	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Respiratory, thoracic and mediastinal disorders Pulmonary embolism	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	1.0% 2/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.74% 3/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.49% 2/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Respiratory, thoracic and mediastinal disorders Pulmonary oedema	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Respiratory, thoracic and mediastinal disorders Respiratory failure	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Skin and subcutaneous tissue disorders Erythrodermic psoriasis	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Skin and subcutaneous tissue disorders Pityriasis rubra pilaris	0.24% 1/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Skin and subcutaneous tissue disorders Urticaria	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Surgical and medical procedures Alcohol detoxification	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.49% 2/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Vascular disorders Arterial stenosis	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Vascular disorders Deep vein thrombosis	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Vascular disorders Hypertension	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Vascular disorders Intra-abdominal haemorrhage	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Vascular disorders Malignant hypertension	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Vascular disorders Peripheral arterial occlusive disease	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.25% 1/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Vascular disorders Shock	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Cardiac disorders Sinus bradycardia	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Infections and infestations Otitis media	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.51% 1/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.

Other adverse events

Other adverse events
Measure	Placebo (CP) n=410 participants at risk Controlled period (Week 0-12) - Placebo group	Ustekinumab 45 mg (CP) n=409 participants at risk Controlled period (Week 0-12) - Ustekinumab 45 mg group	Ustekinumab 90 mg (CP) n=411 participants at risk Controlled period (Week 0-12) - Ustekinumab 90 mg group	Placebo -> Ustekinumab 45 mg (After CP) n=197 participants at risk After Controlled period (Week 12-264) - patients receiving Placebo at Weeks 0 and 4 -\> receiving ustekinumab 45 mg q12wk or q8wk from Week 12 to Week 244. Some patients in this group dose escalated from ustekinumab 45 mg to 90 mg after Week 52.	Placebo -> Ustekinumab 90 mg (After CP) n=195 participants at risk After Controlled period (Week 12-264) - patients receiving Placebo at Weeks 0 and 4 -\> receiving ustekinumab 90 mg q12wk or q8wk from Week 12 to Week 244.	Ustekinumab 45 mg (After CP) n=407 participants at risk After Controlled period (Week 12-264) - patients receiving ustekinumab 45 mg at Weeks 0 and 4 -\> receiving ustekinumab 45 mg q12wk or q8wk from Week 16 to Week 244. Some patients in this group dose escalated from ustekinumab 45 mg to 90 mg after Week 52.	Ustekinumab 90 mg (After CP) n=409 participants at risk After Controlled period (Week 12-264) - patients receiving ustekinumab 90 mg at Weeks 0 and 4 -\> receiving ustekinumab 90 mg q12wk or q8wk from Week 16 to Week 244.
Infections and infestations Pneumonia	0.24% 1/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	5.1% 10/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	3.1% 6/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	1.2% 5/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	2.9% 12/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Infections and infestations Sinusitis	0.98% 4/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.73% 3/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	1.2% 5/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	12.7% 25/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	8.2% 16/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	7.1% 29/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	13.0% 53/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Infections and infestations Upper respiratory tract infection	3.4% 14/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	4.4% 18/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	2.9% 12/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	29.9% 59/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	27.2% 53/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	27.5% 112/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	27.1% 111/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Infections and infestations Urinary tract infection	0.73% 3/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.73% 3/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	3.6% 7/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	3.6% 7/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	3.7% 15/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	5.6% 23/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Infections and infestations Viral upper respiratory tract infection	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.49% 2/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.49% 2/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	4.1% 8/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	4.1% 8/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	5.2% 21/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	4.4% 18/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Injury, poisoning and procedural complications Laceration	0.49% 2/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	5.1% 10/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	3.1% 6/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	3.4% 14/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	4.2% 17/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Injury, poisoning and procedural complications Muscle strain	0.98% 4/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.73% 3/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.49% 2/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	8.1% 16/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	6.2% 12/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	4.2% 17/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	4.2% 17/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Metabolism and nutrition disorders Diabetes mellitus	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	3.0% 6/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	5.6% 11/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	3.4% 14/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	3.4% 14/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Musculoskeletal and connective tissue disorders Arthralgia	2.9% 12/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	3.4% 14/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	2.4% 10/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	10.7% 21/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	9.2% 18/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	9.8% 40/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	14.7% 60/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Musculoskeletal and connective tissue disorders Back pain	1.7% 7/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.73% 3/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	1.7% 7/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	11.2% 22/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	11.8% 23/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	12.5% 51/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	11.0% 45/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Musculoskeletal and connective tissue disorders Pain in extremity	0.98% 4/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.73% 3/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	4.6% 9/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	2.6% 5/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	5.4% 22/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	7.1% 29/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Nervous system disorders Headache	4.1% 17/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	4.6% 19/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	4.6% 19/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	10.7% 21/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	10.8% 21/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	10.6% 43/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	12.5% 51/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Psychiatric disorders Anxiety	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.49% 2/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	5.1% 10/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	2.1% 4/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	3.4% 14/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	3.4% 14/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Psychiatric disorders Depression	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.73% 3/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.49% 2/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	5.6% 11/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	3.6% 7/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	5.4% 22/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	4.2% 17/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Psychiatric disorders Insomnia	0.73% 3/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.73% 3/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.49% 2/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	7.1% 14/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	3.6% 7/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	4.4% 18/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	3.9% 16/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Respiratory, thoracic and mediastinal disorders Cough	1.7% 7/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.73% 3/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.97% 4/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	8.1% 16/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	9.2% 18/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	8.8% 36/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	8.8% 36/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain	0.98% 4/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	1.5% 6/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	1.9% 8/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	3.0% 6/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	8.7% 17/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	3.9% 16/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	3.4% 14/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Vascular disorders Hypertension	1.5% 6/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	1.2% 5/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.97% 4/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	16.2% 32/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	10.3% 20/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	12.3% 50/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	12.5% 51/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Gastrointestinal disorders Diarrhoea	2.7% 11/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	2.2% 9/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	2.7% 11/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	6.6% 13/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	3.6% 7/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	8.6% 35/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	6.6% 27/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Gastrointestinal disorders Gastrooesophageal reflux disease	0.24% 1/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.49% 2/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	5.1% 10/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	3.1% 6/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	4.2% 17/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	3.2% 13/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Gastrointestinal disorders Toothache	0.49% 2/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.73% 3/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.97% 4/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	1.5% 3/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	5.1% 10/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	2.2% 9/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	4.2% 17/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
General disorders Injection site erythema	0.24% 1/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	1.5% 6/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	1.5% 6/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	2.5% 5/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	2.6% 5/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	4.2% 17/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	5.6% 23/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Infections and infestations Bronchitis	1.5% 6/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.73% 3/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.49% 2/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	11.2% 22/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	10.3% 20/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	12.3% 50/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	8.8% 36/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Infections and infestations Gastroenteritis	0.49% 2/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.98% 4/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.49% 2/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	6.6% 13/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	6.7% 13/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	10.6% 43/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	8.6% 35/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Infections and infestations Gastroenteritis viral	0.00% 0/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	5.1% 10/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	3.1% 6/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	3.4% 14/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	3.7% 15/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Infections and infestations Influenza	0.49% 2/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.73% 3/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.97% 4/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	12.7% 25/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	9.7% 19/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	10.3% 42/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	11.7% 48/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Infections and infestations Nasopharyngitis	7.1% 29/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	7.3% 30/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	6.8% 28/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	35.0% 69/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	38.5% 75/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	33.7% 137/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	35.0% 143/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.
Infections and infestations Pharyngitis	0.73% 3/410 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	0.24% 1/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	1.2% 5/411 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	3.6% 7/197 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	4.6% 9/195 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	4.4% 18/407 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.	5.1% 21/409 • Week 264 4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.

Additional Information

Senior Director, Compound Development Team Leader

Centocor Research & Development, Inc.

Phone: 1 215 793-7612

Results disclosure agreements

Principal investigator is a sponsor employee Generally, the only disclosure restriction on the PI is that the sponsor has 60 days to review results communications prior to public release and can embargo communications regarding trial results for a period that does not exceed 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.
Publication restrictions are in place

Restriction type: OTHER